Atwater Malick’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $2.12M | Sell |
55,996
-1,674
| -3% | -$77.2K | 0.47% | 38 |
|
|
2026
Q2 | $2.76M | Sell |
57,670
-4,699
| -8% | -$202K | 0.6% | 31 |
|
|
2026
Q1 | $2.29M | Sell |
62,369
-2,517
| -4% | -$119K | 0.62% | 30 |
|
|
2025
Q4 | $3.3M | Sell |
64,886
-6,561
| -9% | -$336K | 0.91% | 25 |
|
|
2025
Q3 | $3.96M | Sell |
71,447
-94,158
| -57% | -$5.51M | 1.15% | 24 |
|
|
2025
Q2 | $11.4M | Buy |
165,605
+1,736
| +1% | +$118K | 3.62% | 11 |
|
|
2025
Q1 | $11.4M | Buy |
163,869
+1,641
| +1% | +$136K | 3.85% | 10 |
|
|
2024
Q4 | $14M | Sell |
162,228
-4,604
| -3% | -$498K | 4.68% | 7 |
|
|
2024
Q3 | $19.9M | Sell |
166,832
-1,668
| -1% | -$222K | 6.39% | 2 |
|
|
2024
Q2 | $24.1M | Sell |
168,500
-144
| -0.1% | -$19.1K | 8.29% | 1 |
|
|
2024
Q1 | $21.7M | Sell |
168,644
-1,634
| -1% | -$195K | 7.63% | 1 |
|
|
2023
Q4 | $17.6M | Sell |
170,278
-2,314
| -1% | -$229K | 6.9% | 2 |
|
|
2023
Q3 | $15.7M | Sell |
172,592
-2,760
| -2% | -$243K | 6.91% | 2 |
|
|
2023
Q2 | $14.2M | Buy |
175,352
+70
| +0% | +$5.72K | 6.06% | 2 |
|
|
2023
Q1 | $13.9M | Sell |
175,282
-3,270
| -2% | -$232K | 6.54% | 2 |
|
|
2022
Q4 | $12.1M | Sell |
178,552
-538
| -0.3% | -$31.5K | 5.95% | 2 |
|
|
2022
Q3 | $8.92M | Buy |
179,090
+1,396
| +0.8% | +$74.8K | 4.98% | 3 |
|
|
2022
Q2 | $9.9M | Buy |
177,694
+1,410
| +0.8% | +$78.2K | 5.21% | 2 |
|
|
2022
Q1 | $9.8M | Buy |
176,284
+4,888
| +3% | +$251K | 4.73% | 4 |
|
|
2021
Q4 | $9.6M | Sell |
171,396
-1,652
| -1% | -$89.5K | 4.46% | 5 |
|
|
2021
Q3 | $8.31M | Buy |
173,048
+2,134
| +1% | +$103K | 4.39% | 5 |
|
|
2021
Q2 | $7.16M | Buy |
170,914
+7,912
| +5% | +$307K | 3.96% | 9 |
|
|
2021
Q1 | $5.5M | Sell |
163,002
-7,256
| -4% | -$258K | 3.37% | 14 |
|
|
2020
Q4 | $5.95M | Buy |
170,258
+2,762
| +2% | +$95.5K | 3.74% | 11 |
|
|
2020
Q3 | $5.82M | Buy |
167,496
+3,434
| +2% | +$114K | 4.07% | 8 |
|
|
2020
Q2 | $5.37M | Buy |
164,062
+2,670
| +2% | +$85.2K | 4.23% | 7 |
|
|
2020
Q1 | $4.86M | Buy |
161,392
+2,694
| +2% | +$80.2K | 4.66% | 7 |
|
|
2019
Q4 | $4.59M | Buy |
158,698
+5,854
| +4% | +$162K | 3.65% | 15 |
|
|
2019
Q3 | $3.95M | Buy |
152,844
+7,508
| +5% | +$190K | 3.32% | 18 |
|
|
2019
Q2 | $3.71M | Buy |
145,336
+6,102
| +4% | +$151K | 3.4% | 18 |
|
|
2019
Q1 | $3.64M | Buy |
139,234
+5,418
| +4% | +$133K | 3.56% | 17 |
|
|
2018
Q4 | $3.08M | Buy |
+133,816
| New | +$2.97M | 3.45% | 16 |
|
Other funds holding NVO
Atwater Malick's NVO Position: Q3 2026 in Review
Atwater Malick reduced its Novo Nordisk (NVO) stake by 2.9% in Q3 2026, selling an estimated $77.2K and leaving 55,996 shares worth $2.12M. The position accounts for 0.47% of the portfolio, ranked #38.
Atwater Malick first reported a position in NVO in Q4 2018 and has held it in 32 quarters since. The position peaked at $24.1M in Q2 2024. 923 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- Atwater Malick held 55,996 shares of Novo Nordisk worth $2.12M as of Q3 2026.
- Atwater Malick sold 1,674 Novo Nordisk shares in Q3 2026, an estimated $77.2K.
- Novo Nordisk made up 0.47% of Atwater Malick's portfolio in Q3 2026, its #38 holding.
- Atwater Malick first reported a position in Novo Nordisk in Q4 2018 and has held it in 32 quarters since.
- Atwater Malick's Novo Nordisk position peaked at $24.1M in Q2 2024.
- 923 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on Atwater Malick's 13F filing for Q3 2026, filed 15 Oct 2026.